Stocks · Healthcare · Biotechnology
SAB Biotherapeutics, Inc. SABS
$2.98 -2.61% Close, Oct 2, 2026 · NASDAQ · Market cap $271.1M
Next earnings report: Nov 13, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The diluted share count rose 758.1% in a year.
- The stock is in a downtrend: below its 200-day average, with the 50-day average below the 200-day.
- The stock is 35% below its highest close of the past year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 2%
- Revenue growth accelerationTop 46%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 40%
- Accruals (lower is better)Bottom 4%
- Interest coverBottom 10%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 24%
- Free-cash-flow yieldBottom 19%
- EBITDA / enterprise valueTop 48%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 20%
- 6-month returnBottom 22%
- 1-year return vs S&P 500Top 27%
- Distance from 52-week highBottom 38%
- Trend checklist (0–4)Bottom 14%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 14%
- Consecutive EPS beatsBottom 49%
- Share of analysts rating BuyTop 31%
- Upside to consensus price targetTop 12%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 18%
- Maximum drawdown, 3 yearsBottom 18%
- Beta vs S&P 500 (lower is better)Top 42%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -100.0% | -100.0% | → |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -100.0% | -100.0% | → | Bottom 2% |
| Return on invested capital | -31.6% | — | Bottom 40% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 23.3%
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -310.3×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -129.47%
- Shareholder yield
- -129.47%
- Share count change, 1 year
- +758.1%
- Share count change, 3-year CAGR
- +151.0%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 6, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 1
- Beats in the last 8 reports
- 3 of 8
- Average EPS surprise, last 4
- -49.3%
- Average 2-day reaction, last 8
- +0.3%
- Positive 20 days after report
- 5 of 8
Analysts
- Consensus price target
- $11.33
- Target vs current price
- +280.2%
- Analysts with a rating
- 8
- Share rating Buy or Strong Buy
- 88%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 6, 2026 | +1.1% | +2.1% | +0.8% | -0.5% | — |
| May 12, 2026 | -75.0% | -2.7% | -4.3% | -9.7% | +3.5% |
| Mar 9, 2026 | -187.5% | +1.3% | +9.5% | +1.6% | -8.2% |
| Nov 14, 2025 | +64.4% | +4.5% | +22.6% | +22.9% | +34.8% |
| Aug 7, 2025 | -32.9% | +1.8% | -1.8% | +3.2% | +37.4% |
| May 9, 2025 | +44.0% | +4.1% | +12.8% | +5.2% | +33.7% |
| Mar 28, 2025 | -6.0% | -4.5% | -23.9% | +12.9% | +16.1% |
| Nov 6, 2024 | -4.7% | -4.6% | -17.4% | -30.2% | -46.1% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.28 | -$0.28 | +1.1% | — |
| May 12, 2026 | -$0.35 | -$0.20 | -75.0% | — |
| Mar 9, 2026 | -$0.46 | -$0.16 | -187.5% | — |
| Nov 14, 2025 | -$0.21 | -$0.59 | +64.4% | — |
| Aug 7, 2025 | -$1.09 | -$0.82 | -32.9% | — |
| May 9, 2025 | -$0.56 | -$1.00 | +44.0% | — |
| Mar 28, 2025 | -$1.23 | -$1.16 | -6.0% | $100,000 |
| Nov 6, 2024 | -$1.12 | -$1.07 | -4.7% | -$410 |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| Free-cash-flow yield | -26.81% | — | — | Bottom 19% |
| Earnings yield | -28.86% | — | — | Bottom 24% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -4.1%
- 200-day average slope (20 days)
- -1.1%
- Distance from 50-day average
- -16.8%
- Distance from 200-day average
- -21.1%
- RSI (14)
- 25.6
- Relative volume
- 0.68×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 36.7%
- Volatility vs own 5-year history
- 2th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.98
- Correlation with S&P 500
- 0.16
- Current drawdown from 1-year high
- -35.1%
- Maximum drawdown, 3 years
- -89.0%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Dec 1, 2021 | Apr 7, 2025 | -99.0% | 839 days | Not yet recovered |
| Oct 18, 2021 | Oct 25, 2021 | -30.3% | 5 days | 17 days (Nov 17, 2021) |
| Nov 17, 2021 | Nov 23, 2021 | -23.0% | 4 days | 5 days (Dec 1, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $271.1M
- EPS, diluted (TTM)
- -$0.86
- Revenue (TTM)
- $0
- 52-week range
- $1.94 – $5.15
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $60.9M | $23.9M | $2.2M | $1.3M | $0 |
| Gross profit | $59.2M | $20.6M | -$1.5M | -$3.5M | -$3.1M |
| Operating income | -$13.4M | -$28.9M | -$38.1M | -$42.9M | -$49.0M |
| Net income | -$17.1M | -$18.7M | -$42.2M | -$34.1M | $13.3M |
| EPS (diluted) | -$6.30 | -$4.31 | -$7.64 | -$3.68 | -$0.79 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $114,698 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$10.3M | -$11.4M | -$5.2M | -$10.1M | $45.4M | -$16.9M | -$18.9M | -$22.5M |
| EPS (diluted) | -$1.12 | -$1.23 | -$0.56 | -$1.09 | $0.58 | -$0.81 | -$0.35 | -$0.28 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $2.0M | -$23.5M | -$25.1M | -$34.3M | -$44.8M |
| Capital expenditure | -$10.9M | -$2.2M | -$197,154 | -$337,262 | -$933,151 |
| Free cash flow | -$9.0M | -$25.6M | -$25.3M | -$34.6M | -$45.7M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $6,750 | $2.2M | $0 | $20,409 | $168.7M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $102.6M
- Total assets
- $238.2M
- Total liabilities
- $23.4M
- Total debt
- $5.1M
- Net debt
- -$3.1M
- Shareholders’ equity
- $214.8M
As of Jun 30, 2026 (filed Aug 6, 2026).
Short interest
- Shares sold short
- 3,603,065
- Days to cover
- 13.37
- Change vs previous report
- -12.6%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Jan 5, 2024
- 1-for-10